Relevant bibliographies by topics / Pharyngeal gonorrhoea

Academic literature on the topic 'Pharyngeal gonorrhoea'

Author: Grafiati
Published: 4 June 2021
Last updated: 19 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharyngeal gonorrhoea.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharyngeal gonorrhoea"

1

Balachandran, T., A. P. Roberts, B. A. Evans, and B. S. Azadian. "Single-Dose Therapy of Anogenital and Pharyngeal Gonorrhoea with Ciprofloxacin." International Journal of STD & AIDS 3, no. 1 (January 1992): 49–51. http://dx.doi.org/10.1177/095646249200300112.

Full text
Abstract:
A single dose of ciprofloxacin, 250 mg by mouth, was used in an open study to treat pharyngeal or rectal gonorrhoea or both in 64 patients (32 men and 32 women). The study also included 151 men with urethral gonorrhoea and 53 women with cervical or urethral gonorrhoea. Ciprofloxacin cured 63 (98%) patients with pharyngeal or rectal gonorrhoea (including 5 patients with penicillinase-producing Neisseria gonorrhoeae; PPNG), 147 (97%) men with urethral gonorrhoea (including 8 with PPNG) and 52 (98%) women with cervical or urethral gonorrhoea. All the isolates of N. gonorrhoeae were sensitive to 0.03 mg/l of ciprofloxacin. Five of the 6 patients with treatment failure were subsequently cured by a single oral dose of ciprofloxacin 250 mg. None of the patients reported an adverse reaction. Ciprofloxacin 250 mg as a single oral dose is effective and safe in treating patients with pharyngeal or rectal gonorrhoea, including those with PPNG strains.
APA, Harvard, Vancouver, ISO, and other styles
2

McMillan, A., H. Young, and A. Moyes. "Rectal Gonorrhoea in Homosexual Men: Source of Infection." International Journal of STD & AIDS 11, no. 5 (May 2000): 284–87. http://dx.doi.org/10.1177/095646240001100502.

Full text
Abstract:
The objective of this retrospective study was to determine the possible source of infection in homosexual men with rectal gonorrhoea: the probable source of rectal gonorrhoea was identified in 46/155 cases. Although the urethra was the site of infection in 33 (72%) of these contacts, only pharyngeal gonorrhoea was identified in 9 (20%) men. In 25/26 cases, there was concordance in the auxo/serotypes of Neisseria gonorrhoeae between contacts with urethral gonorrhoea and the index men with rectal gonorrhoea. Eleven out of 12 pharyngeal isolates were of the same auxo/serotype as the index cases. This study supports the hypothesis that rectal gonorrhoea in homosexual men can be acquired from the oropharynx. Because infection at this site is an independent risk factor for acquisition of HIV, screening for rectal and pharyngeal gonorrhoea should be offered to men who have sex with men, even when there is no history of unprotected receptive anal intercourse.
APA, Harvard, Vancouver, ISO, and other styles
3

Marangoni, Antonella, Giacomo Marziali, Melissa Salvo, Antonietta D’Antuono, Valeria Gaspari, Claudio Foschi, and Maria Carla Re. "Mosaic structure of the penA gene in the oropharynx of men who have sex with men negative for gonorrhoea." International Journal of STD & AIDS 31, no. 3 (January 30, 2020): 230–35. http://dx.doi.org/10.1177/0956462419889265.

Full text
Abstract:
The oropharynx represents a crucial site for the emergence of multi-drug resistance in Neisseria gonorrhoeae. The mosaic penA alleles, associated with decreased susceptibility to cephalosporins, have emerged by DNA recombination with partial penA genes, particularly those from commensal pharyngeal Neisseria species. Here, we investigated the prevalence of the mosaic structure of the penA gene in the oropharynx of men who have sex with men testing negative for pharyngeal gonorrhoea. From January 2016 to June 2018, 351 gonorrhoea-negative men who have sex with men attending a sexually transmitted infection clinic in Italy were enrolled. Pharyngeal swabs underwent a real-time polymerase chain reaction (PCR) for the detection of the mosaic penA gene. In case of positivity, PCR products were sequenced and searched against several sequences of Neisseria strains. Overall, 31 patients (8.8%) were found positive for the presence of the mosaic penA gene. The positivity was significantly associated with previous cases of pharyngeal gonorrhoea (relative risk [RR]: 3.56, 95% confidence interval 1.44–8.80) and with recent exposure to beta-lactams (RR: 4.29, 95% confidence interval 2.20–8.38). All penA-positive samples showed a high relatedness (90–99%) with mosaic-positive Neisseria strains. Our data underline that commensal Neisseria species of the oropharynx may be a significant reservoir for genetic material conferring antimicrobial resistance in N. gonorrhoeae.
APA, Harvard, Vancouver, ISO, and other styles
4

Richardson, Daniel, Alice Pickering, Daniel Trotman, Kayleigh Nichols, Zoe Buss, John Devlin, and Fionnuala Finnerty. "Pharyngeal gonorrhoea in men who have sex with men." International Journal of STD & AIDS 32, no. 5 (February 3, 2021): 449–52. http://dx.doi.org/10.1177/0956462420975627.

Full text
Abstract:
Pharyngeal gonorrhoea is important in the transmission dynamics of gonorrhoea, and generation of antimicrobial resistance and the performing of culture remains vital. We reviewed the notes of men who have sex with men (MSM) presenting to our clinic with a positive pharyngeal NAAT for gonorrhoea between January and December 2019. There were 383 cases of NAAT-positive pharyngeal gonorrhoea, and 28 (7%, 95% CI = 5.11–10.36) reported sore throat at presentation. Pharyngeal cultures were taken from 270/383 (70%), and 73/270 (27%) were culture positive with available antimicrobial sensitivities. Overall, the presence of pharyngeal symptoms was not associated with pharyngeal chlamydia (OR = 1.6, CI = 0.19–13.32, p = 0.7), HIV status (OR = 1.1, CI = 0.47–2.57, p = 0.8), positive cultures (OR = 1.9, CI = 0.78–4.62, p = 0.2) or age ( p = 0.3). Routine screening of MSM for pharyngeal gonorrhoea is important to maintain surveillance and measures need to be taken to improve pharyngeal culture sampling from MSM.
APA, Harvard, Vancouver, ISO, and other styles
5

Kong, Fabian Y. S., Christina L. Hatzis, Andrew Lau, Deborah A. Williamson, Eric P. F. Chow, Christopher K. Fairley, and Jane S. Hocking. "Treatment efficacy for pharyngeal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials." Journal of Antimicrobial Chemotherapy 75, no. 11 (August 3, 2020): 3109–19. http://dx.doi.org/10.1093/jac/dkaa300.

Full text
Abstract:
Abstract Background Rising gonorrhoea rates require highly effective treatments to reduce transmission and prevent development of antimicrobial resistance. Currently the most effective treatments for pharyngeal gonorrhoea remain unclear. This review aimed to estimate treatment efficacy for pharyngeal gonorrhoea. Methods Online bibliographic databases were searched for the period 1 January 2000 to 17 September 2019 for treatments of gonorrhoea. All randomized controlled trials (RCTs) with data on pharyngeal gonorrhoea among participants aged 15 years or above, published in English, were included. Meta-analyses (random effects) were used to estimate the treatment efficacy, defined as microbiological cure, among currently recommended monotherapies and dual therapies, previously recommended but no longer used regimens and emerging drugs under evaluation. Side effects were also summarized. The study protocol was registered on PROSPERO (CRD42020149278). Results There were nine studies that included 452 participants studying 19 treatment regimens. The overall treatment efficacy for pharyngeal gonorrhoea was 98.1% (95% CI: 93.8%–100%; I2 = 57.3%; P < 0.01). Efficacy was similar for single (97.1%; 95% CI: 90.8%–100.0%; I2 = 15.6%; P = 0.29) and dual therapies (98.0%; 95% CI: 91.4%–100%; I2 = 79.1%; P < 0.01). Regimens containing azithromycin 2 g or ceftriaxone were similarly efficacious. The summary efficacy estimate for emerging drugs was 88.8% (95% CI: 76.9%–97.5%; I2 = 11.2%; P = 0.34). Small sample sizes in each trial was a major limitation. Conclusions Regimens containing ceftriaxone or azithromycin 2 g, alone or as part of dual therapies are the most efficacious for pharyngeal gonorrhoea. Further pharyngeal-specific RCTs with adequate sample sizes are needed.
APA, Harvard, Vancouver, ISO, and other styles
6

Janier, M., F. Lassau, I. Casin, and P. Morel. "Pharyngeal gonorrhoea: the forgotten reservoir." Sexually Transmitted Infections 79, no. 4 (August 1, 2003): 345. http://dx.doi.org/10.1136/sti.79.4.345.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lister, N. A., A. Smith, T. Read, and C. K. Fairley. "Testing men who have sex with men for Neisseria gonorrhoeae and Chlamydia trachomatis prior to the introduction of guidelines at an STD clinic in Melbourne." Sexual Health 1, no. 1 (2004): 47. http://dx.doi.org/10.1071/sh03005.

Full text
Abstract:
Background: Guidelines for testing men who have sex with men (MSM) were published in 2002. They did not recommend asymptomatic screening for urethral gonorrhoea or pharyngeal screening for chlamydia. To determine if these guidelines were appropriate, we audited gonorrhoea and chlamydia testing of MSM at our centre. Methods: We carried out two audits at our Centre between August 2001 to July 2002. The first was an audit of testing MSM for gonorrhoea and/ or chlamydia over 12 days. The second was an audit of all positive tests over this 12-month period for gonorrhoea or chlamydia among MSM. Results: During the 12 selected days 89 of 286 men tested (31%) were MSM. Among the MSM testing positive for gonorrhoea and/ or chlamydia infection (15, 17%), symptomatic urethral infection was the most common (n = 8). No rectal and pharyngeal infections had site-specific symptoms. Based on the guidelines, 100 of the 334 tests ordered (30%) were not recommended according to the guidelines, and none of these 100 tests yielded a positive result. Over the 12-month audit period, 135 MSM were diagnosed with gonorrhoea and/ or chlamydia. For gonorrhoea, site specific symptoms were present in 42 of 43 cases of urethral infection (98%), six of 23 cases of rectal infection (26%), and no cases of pharyngeal infection had symptoms. For chlamydia, site-specific symptoms were present in 29 of 48 cases of urethral infection (60%), six of 33 cases of rectal infection (18%), and in one of the two cases of pharyngeal chlamydia identified. A substantial proportion of cases occurred in clients with HIV infection (21, 16%). Conclusions: These findings strongly support screening among MSM and in particular not testing asymptomatic MSM for urethral gonorrhoea or any MSM for pharyngeal Chlamydia.
APA, Harvard, Vancouver, ISO, and other styles
8

Barbee, Lindley A., and Matthew R. Golden. "Aztreonam for Neisseria gonorrhoeae: a systematic review and meta-analysis." Journal of Antimicrobial Chemotherapy 75, no. 7 (April 7, 2020): 1685–88. http://dx.doi.org/10.1093/jac/dkaa108.

Full text
Abstract:
Abstract Background Ceftriaxone is the only consistently active antimicrobial agent recommended for the treatment of Neisseria gonorrhoeae. Although some new antimicrobials are in development, the necessity to expand treatment options in the near term may require using older drugs that have not been widely used to treat gonorrhoea. Methods We conducted a literature review of clinical trials and case series, published from 1983 to 2017, reporting treatment efficacy results following administration of 1 g aztreonam intramuscularly or IV for uncomplicated gonococcal infections. We summed trial data, stratified by anatomical site of infection, and calculated summary efficacy estimates and 95% CI for each site of infection. Results The 10 identified clinical trials enrolled 678, 38 and 16 individuals with urogenital, rectal and pharyngeal gonorrhoea, respectively. Aztreonam had an efficacy of 98.6% (95% CI: 97.5%–99.4%) for urogenital, 94.7% (95% CI: 82.3%–99.4%) for rectal and 81.3% (95% CI: 54.4%–96.0%) for pharyngeal gonococcal infections. Conclusions Although most clinical trials included in this meta-analysis were conducted >30 years ago, aztreonam appears to have excellent efficacy for urogenital gonorrhoea; its efficacy at extragenital sites remains uncertain.
APA, Harvard, Vancouver, ISO, and other styles
9

Comninos, Nicholas Byron, Linda Garton, Rebecca Guy, Denton Callander, Christopher K. Fairley, Andrew E. Grulich, Basil Donovan, Sian Louise Goddard, Alison Rutherford, and David J. Templeton. "Increases in pharyngeal Neisseria gonorrhoeae positivity in men who have sex with men, 2011–2015: observational study." Sexually Transmitted Infections 96, no. 6 (October 17, 2019): 432–35. http://dx.doi.org/10.1136/sextrans-2019-054107.

Full text
Abstract:
ObjectivesPharyngeal gonorrhoea disproportionately affects men who have sex with men (MSM). We explored temporal trends in pharyngeal gonorrhoea positivity among MSM compared with anorectal and urogenital positivity.MethodsData (2011–2015) were extracted from 41 publicly funded sexual health clinics participating in a national surveillance network. Positivity was defined as the proportion of first-visit testing occasions where gonorrhoea was detected. Logistic regression explored trends in positivity and correlates of positive pharyngeal tests.ResultsFrom 2011 to 2015, 24 792 MSM tested (16 710 pharyngeal, 19 810 urogenital and 15 974 anorectal first-visit tests). Pharyngeal positivity increased by 183% from 139/3509 (4.0%) in 2011 to 397/3509 (11.3%) in 2015, p-trend <0.001; urogenital positivity by 39% from 257/4615 (5.6%) to 295/3783 (7.8%), p-trend=0.006; and anorectal positivity by 87% from 160/3469 (4.6%) to 286/3334 (8.6%), p-trend <0.001. The annual temporal increase in positivity was greater in the pharynx (OR 1.33; 95% CI 1.27 to 1.38) than at urogenital (OR 1.06; 95% CI 1.02 to 1.10) and anorectal (OR 1.16; 95% CI 1.11 to 1.21) sites. Factors independently associated with pharyngeal gonorrhoea were: younger age (p<0.001), higher numbers of recent sexual partners (p-trend=0.004), contact with a person with a diagnosed STI (p<0.001), injecting drug use (p<0.001), anogenital symptoms (p<0.001) and HIV-positive status (p=0.050).ConclusionTemporal increases in gonorrhoea positivity occurred at all anatomical sites, with the greatest increase in the pharynx. Risk factors could be used to help to develop testing and prevention strategies among MSM at highest risk. Strengthening sexual health service delivery, testing and surveillance remain priorities for pharyngeal gonorrhoea control.
APA, Harvard, Vancouver, ISO, and other styles
10

Tapsall, John, Phillip Read, Christopher Carmody, Christopher Bourne, Sanghamitra Ray, Athena Limnios, Theo Sloots, and David Whiley. "Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods." Journal of Medical Microbiology 58, no. 5 (May 1, 2009): 683–87. http://dx.doi.org/10.1099/jmm.0.007641-0.

Full text
Abstract:
Diagnostic, genotypic and antibiotic-resistance determinants of Neisseria gonorrhoeae were analysed by molecular methods to verify the failure of ceftriaxone treatment in two cases of pharyngeal gonorrhoea. Monoplex assays were needed to define competitive inhibition of a positive Chlamydia PCR in a duplex assay. Different penA changes were detected in the N. gonorrhoeae isolated from the two cases. These were associated with raised ceftriaxone MICs of 0.03 and 0.016 mg l−1, which may have contributed to the treatment failures in these cases.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharyngeal gonorrhoea"

1

Templeton, David James Public Health &amp Community Medicine Faculty of Medicine UNSW. "The role of circumcision and pharyngeal STIs in HIV and STI transmission among homosexual men." Publisher:University of New South Wales. Public Health & Community Medicine, 2008. http://handle.unsw.edu.au/1959.4/43239.

Full text
Abstract:
This thesis presents data on two separate areas relevant to the prevention of HIV and sexually transmitted infection (STI) transmission in homosexual men. These data arise from the community-based Health in Men (HIM) cohort of HIV-negative homosexual men in Sydney. First, the association of circumcision status with HIV and STIs was examined. Older age, ethnicity and country of birth were demographic factors independently associated with circumcision status. Self-report was a valid measure of circumcision status in this population. Overall, being circumcised was associated with a non-significant reduced risk of HIV seroconversion in the HIM cohort (HR 0.76, 95% CI 0.41-1.41, p=0.381). Among the one-third of participants predominantly practising the insertive role in anal intercourse (AI), being circumcised was associated with a significantly reduced risk of HIV infection (HR 0.15, 95% CI 0.03-0.80, p=0.026). Circumcised HIM participants also had a lower risk of incident syphilis (HR 0.35, 95% CI 0.15-0.84, p=0.019), however circumcision status had no significant effect on the remainder of prevalent and incident STIs examined. Second, risk factors for pharyngeal gonorrhoea and chlamydia were investigated. The BD ProbeTec nucleic acid amplification test (NAAT) had a positive predictive value (PPV) for pharyngeal gonorrhoea diagnosis of only 30.4% (95% CI 25.2-36.1%) when compared to a previously validated NAAT targeting the gonococcal porA pseudogene. Pharyngeal gonorrhoea was common in HIM, mostly occurred without concurrent anogenital infection and may frequently spontaneously resolve. Infection was independently associated with younger age (p-trend=0.001), higher number of male partners (p-trend=0.002), contact with gonorrhoea (p<0.001) and insertive oro-anal sex with casual partners (p-trend=0.044). Pharyngeal chlamydia was less common but a high prevalence/incidence ratio suggested that infection may persist in the pharynx for long periods. Pharyngeal chlamydia was independently associated with receptive penile-oral sex with casual partners (p-trend=0.009). In conclusion, circumcision may have a role as an HIV prevention intervention among the subgroup of homosexual men who predominantly practise insertive rather than receptive AI. Regular screening of the pharynx including a validated supplemental NAAT for gonorrhoea diagnosis may prevent much transmission to anogenital sites, whereas chlamydia occurs too infrequently in the pharynx to recommend routine screening in homosexual men.
APA, Harvard, Vancouver, ISO, and other styles
2

Leon, Segundo R., Eddy R. Segura, Kelika A. Konda, Juan A. Flores, Alfonso Silva-Santisteban, Jerome T. Galea, Thomas J. Coates, Jeffrey D. Klausner, and Carlos F. Caceres. "High prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections in anal and pharyngeal sites among a community-based sample of men who have sex with men and transgender women in Lima, Peru." BMJ Publishing Group Ltd, 2016. http://hdl.handle.net/10757/595419.

Full text
Abstract:
This study aimed to characterise the epidemiology of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections among men who have sex with men (MSM) and transgender women (TW) in Lima, Peru.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pharyngeal gonorrhoea"

1

Levy, Vivian, Craig S. Blackmore, and Jeffrey D. Klausner. "Self-Collection of Specimens for Nucleic Acid-Based Diagnosis of Pharyngeal, Cervicovaginal, Urethral, and Rectal Neisseria gonorrhoeae and Chlamydia trachomatis Infections." In Methods in Molecular Biology, 407–18. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-937-2_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharyngeal gonorrhoea"

1

Stuart, S., D. Richardson, C. Iwuji, and S. Soni. "P212 Standardising pharyngeal sampling for clinician-taken gonorrhoea culture specimens." In Abstracts for the STI & HIV World Congress, July 14–17 2021. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/sextrans-2021-sti.300.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chow, Eric PF, Sandra Walker, Tiffany Phillips, and Christopher K. Fairley. "O02.6 Behavioural change to reduce the risk of pharyngeal gonorrhoea in men who have sex with men." In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Trotman, D., A. Pickering, K. Nicols, Z. Buss, J. Devlin, F. Finnerty, and D. Richardson. "P033 The sensitivity and clinical features of Pharyngeal gonorrhoea cultures in men who have sex with men." In Abstracts for the STI & HIV World Congress, July 14–17 2021. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/sextrans-2021-sti.180.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ross, Jonathan DC, Jan Harding, Lelia Duley, Alan A. Montgomery, Trish Hepburn, Wei Tan, Clare Brittain, et al. "LB1.5 The efficacy and safety of gentamicin for the treatment of genital, pharyngeal and rectal gonorrhoea: a randomised controlled trial." In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.106.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Barbee, Lindley, Olusegun Soge, Jennifer Morgan, Angela Leclair, Tamara Bass, James Hughes, and Matthew Golden. "O06.1 Gentamicin for pharyngeal gonorrhea: a single-arm, non-blinded clinical trial." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.134.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Melendez, J., E. Mande, A. Onzia, P. Kyambadde, M. Lamorde, Y. Manabe, and M. Hamill. "P150 Characterization of pharyngeal gonorrhea in Ugandan men with urethral discharge syndrome." In Abstracts for the STI & HIV World Congress, July 14–17 2021. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/sextrans-2021-sti.258.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rob, Filip, Barbora Klubalová, Jana Hercogová, and Magnus Unemo. "P650 Randomized clinical trial comparing gentamicin+azithromycin vs. ceftriaxone + azithromycin for rectal and pharyngeal gonorrhea." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.718.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Barbee, Lindley, Olusegun Soge, Micaela Haglund, Winnie Yeung, James Hughes, Christine Khosropour, and Matthew Golden. "O02.4 Incidence and duration of pharyngeal and rectal gonorrhea and chlamydia among high-risk men who have sex with men (MSM)." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fairley, Christopher. "D01.1 Among men who have sex with men, pharyngeal infection contributes more to population levels of gonorrhea transmission than urethral infection, rectal infection, or both (for the motion)." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Handsfield, H. Hunter. "D01.2 Among men who have sex with men, pharyngeal infection contributes more to population levels of gonorrhea transmission than urethral infection, rectal infection, or both (Against the motion)." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharyngeal gonorrhoea' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography